DE69736745D1 - Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe - Google Patents

Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe

Info

Publication number
DE69736745D1
DE69736745D1 DE69736745T DE69736745T DE69736745D1 DE 69736745 D1 DE69736745 D1 DE 69736745D1 DE 69736745 T DE69736745 T DE 69736745T DE 69736745 T DE69736745 T DE 69736745T DE 69736745 D1 DE69736745 D1 DE 69736745D1
Authority
DE
Germany
Prior art keywords
vitamin
delayed
sustained release
formulations
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69736745T
Other languages
German (de)
English (en)
Inventor
W Bishop
C Knutson
R Valliere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bone Care International Inc
Original Assignee
Bone Care International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bone Care International Inc filed Critical Bone Care International Inc
Application granted granted Critical
Publication of DE69736745D1 publication Critical patent/DE69736745D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69736745T 1996-12-30 1997-12-10 Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe Expired - Lifetime DE69736745D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/775,447 US5795882A (en) 1992-06-22 1996-12-30 Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
PCT/US1997/022034 WO1998029105A2 (en) 1996-12-30 1997-12-10 Method of treating prostatic diseases using delayed and/or sustained release vitamin d formulations

Publications (1)

Publication Number Publication Date
DE69736745D1 true DE69736745D1 (de) 2006-11-09

Family

ID=25104456

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69736745T Expired - Lifetime DE69736745D1 (de) 1996-12-30 1997-12-10 Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe

Country Status (15)

Country Link
US (1) US5795882A (enExample)
EP (1) EP0951286B1 (enExample)
JP (1) JP2001512418A (enExample)
KR (1) KR20000062405A (enExample)
CN (1) CN100345547C (enExample)
AT (1) ATE340581T1 (enExample)
AU (1) AU724153B2 (enExample)
BR (1) BR9715022A (enExample)
CA (1) CA2276465A1 (enExample)
DE (1) DE69736745D1 (enExample)
HU (1) HUP0003526A2 (enExample)
MX (1) MXPA99006988A (enExample)
NZ (1) NZ336511A (enExample)
PL (1) PL334348A1 (enExample)
WO (1) WO1998029105A2 (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009958A1 (en) * 1991-01-08 2004-01-15 Bone Care International, Inc. Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
US6538037B2 (en) * 1991-01-08 2003-03-25 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
TW382595B (en) * 1993-10-15 2000-02-21 Merck & Co Inc Pharmaceutical composition for use in arresting and reversing androgenic alopecia
US5547957A (en) 1993-10-15 1996-08-20 Merck & Co., Inc. Method of treating androgenic alopecia with 5-α reductase inhibitors
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
FR2759293B1 (fr) * 1997-02-11 1999-04-30 Ethypharm Lab Prod Ethiques Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
NZ336924A (en) * 1997-02-13 2001-06-29 Bone Care Int Inc Targeted therapeutic delivery of vitamin D compounds via a Vitamin D conjugate
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
US20020076442A1 (en) * 1997-09-02 2002-06-20 Martin Burke Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
US6849616B1 (en) * 1998-03-27 2005-02-01 Pharmacia Italia S.P.A. Methods to potentiate intravenous estramustine phosphate
JP2002509888A (ja) 1998-03-27 2002-04-02 オレゴン ヘルス サイエンシーズ ユニバーシティー 腫瘍および他の過増殖性疾患の治療におけるビタミンｄおよびその類似体
US6479474B2 (en) * 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
JP2004504295A (ja) * 2000-07-18 2004-02-12 ボーン　ケア　インターナショナル　インコーポレイテッド 安定化１α−ヒドロキシビタミンＤ
AU2002228648A1 (en) * 2000-11-16 2002-05-27 Pharmacia And Upjohn Company Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists
US20040071789A1 (en) * 2002-02-14 2004-04-15 Baron John A Calcium supplementation to reduce prostate cancer risk
US7129230B2 (en) * 2001-03-12 2006-10-31 Nestec S.A. Method and product for treating cancer in pets
CN100391464C (zh) * 2001-12-03 2008-06-04 诺瓦西股份有限公司 含活性维生素d化合物的药物组合物
US20080260834A1 (en) * 2002-08-20 2008-10-23 Martin Burke Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
AU2003273318A1 (en) * 2002-09-12 2004-04-30 University Of Chicago Monitoring and diagnosis of gastric emptying and gastroparesis
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
WO2004047673A2 (en) * 2002-11-21 2004-06-10 Novacea, Inc. Treatment of liver disease with active vitamin d compounds
CA2528359A1 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments
WO2004110380A2 (en) * 2003-06-11 2004-12-23 Novacea, Inc. Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
WO2005011660A1 (en) * 2003-07-29 2005-02-10 Abbott Laboratories Use of vitamin d to down regulate the renin-angiotensin-aldosterone system
EP1664784A1 (en) * 2003-09-17 2006-06-07 Guava Technologies, Inc. Compositions and methods for analysis of target analytes
US20070054887A1 (en) * 2003-09-24 2007-03-08 Bioxell S.P.A Methods for treating bladder dysfunction
US7332482B2 (en) * 2003-09-24 2008-02-19 Bioxell S.P.A. Method for treating benign prostatic hyperplasia
WO2005117542A2 (en) * 2004-05-10 2005-12-15 Novacea, Inc. Treatment of pancreatic cancer with active vitamin d compounds in combination with other treatments
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
CA2586679A1 (en) * 2004-11-12 2006-05-18 Bioxell Spa Combined use of vitamin d derivatives and anti-proliferative agents for treating bladder cancer
US20070122477A1 (en) * 2005-10-12 2007-05-31 Cytochroma, Inc. Methods and articles for treating 25-hydroxyvitamin D insufficiency and deficiency
ATE508750T1 (de) * 2005-12-12 2011-05-15 Women And Infants Hospital Of Rhode Island Derivate von vitamin d und ihre verwendung in der therapie
PT3095447T (pt) 2006-02-03 2022-01-24 Opko Renal Llc Tratamento da insuficiência e deficiência de vitamina d com 25-hidroxivitamina d2 e 25-hidroxivitamina d3
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
DK2037936T3 (da) 2006-06-21 2014-09-22 Opko Renal Llc Fremgangsmåde til behandling og forebyggelse af sekundær hyperparathyroidisme
ES3047207T3 (en) 2007-04-25 2025-12-03 Opko Renal Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
KR101691876B1 (ko) 2007-04-25 2017-01-02 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
EP2148685A4 (en) * 2007-04-25 2010-07-28 Cytochroma Inc METHODS AND COMPOUNDS FOR THERAPY BASED ON VITAMIN D
CA2683628C (en) * 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
ES2593356T3 (es) 2008-04-02 2016-12-07 Opko Ireland Global Holdings, Ltd. Métodos, composiciones, usos y kits útiles para la deficiencia de la vitamina D y trastornos relacionados
WO2010075537A1 (en) * 2008-12-23 2010-07-01 Teva Pharmaceutical Industries Ltd. Formulations comprising vitamin d or derivatives thereof
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
US8999393B1 (en) * 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
CN103142555B (zh) * 2013-03-21 2014-10-01 青岛正大海尔制药有限公司 一种阿法骨化醇缓释胶囊及其制备方法
CN103142554B (zh) * 2013-03-21 2014-11-12 青岛正大海尔制药有限公司 骨化三醇控释胶囊及其制备方法
CN103142537B (zh) * 2013-03-21 2014-11-12 青岛正大海尔制药有限公司 骨化三醇缓释剂片
CN103142553B (zh) * 2013-03-21 2014-10-01 青岛正大海尔制药有限公司 一种骨化三醇缓释胶囊及其制备方法
JP6282939B2 (ja) * 2014-06-05 2018-02-21 株式会社ファンケル 耐酸性錠剤
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
KR20180123100A (ko) 2016-03-28 2018-11-14 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법
KR102121400B1 (ko) * 2018-07-31 2020-06-17 (주)에이치케이바이오텍 신령버섯균사체 액체배양 추출물을 포함하는 전립선 비대증의 예방 또는 치료용 조성물
EP3843706A1 (en) 2018-08-31 2021-07-07 OPKO Ireland Global Holdings, Ltd. Vitamin d pediatric dosage forms, methods of making and using
IT201900003843A1 (it) * 2019-03-15 2020-09-15 Lo Li Pharma Srl Trattamento di fibromi con vitamina D e un agente come l'epigallocatechina gallato (EGCG)
CN110917169A (zh) * 2019-12-11 2020-03-27 正大制药（青岛）有限公司 帕立骨化醇胶囊剂及其制备方法
CN110917163A (zh) * 2019-12-11 2020-03-27 正大制药（青岛）有限公司 一种帕立骨化醇固体口服制剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2216719A (en) * 1935-07-06 1940-10-08 Hartford Nat Bank & Trust Co Vitamin
US2434015A (en) * 1942-11-21 1948-01-06 Du Pont Stable provitamin d composition
US4230701A (en) * 1979-03-21 1980-10-28 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4335120A (en) * 1979-03-21 1982-06-15 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
JPS57149224A (en) * 1981-03-13 1982-09-14 Chugai Pharmaceut Co Ltd Tumor-suppressing agent
EP0070588B1 (en) * 1981-07-17 1986-05-07 Duphar International Research B.V Method of preparing 1-alpha-hydroxyvitamin d and 1-alpha-hydroxy-previtamin d compounds, and adduct of a previtamin d or tachysterol compound with a suitable dienophile
JPS5910562A (ja) * 1982-07-07 1984-01-20 Teijin Ltd プレ−１α−ヒドロキシコレカルシフエロ−ル類の製造法
WO1984004527A1 (en) * 1983-05-09 1984-11-22 Wisconsin Alumni Res Found PROCESS FOR THE PREPARATION OF 1alpha,25-DIHYDROXYLATED VITAMIN D2 AND RELATED COMPOUNDS
US4505906A (en) * 1984-01-30 1985-03-19 Wisconsin Alumni Research Foundation Hydroxyvitamin D2 isomers
US4684524A (en) * 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4728643A (en) * 1984-11-02 1988-03-01 The General Hospital Corporation Method of treating psoriasis
WO1986005395A1 (fr) * 1985-03-14 1986-09-25 Chugai Seiyaku Kabushiki Kaisha Composition de traitement de dermatoses
ZA886284B (en) * 1987-08-31 1990-04-25 Advanced Polymer Systems Inc Controlled release formulations
WO1990009179A1 (en) * 1989-02-16 1990-08-23 University Of Georgia Research Foundation, Inc. Treatment of tibial dyschondroplasia
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
US5013728A (en) * 1990-05-04 1991-05-07 Colgate - Palmolive Company Composition for treating osteoporosis and hormonal imbalance
JPH04198129A (ja) * 1990-11-28 1992-07-17 Sumitomo Pharmaceut Co Ltd 活性型ビタミンｄ↓３類含有組成物
IL110117A0 (en) * 1994-06-24 1994-10-07 Univ Ben Gurion Pharmaceutical compositions comprising vitamin-d analogs
NZ307549A (en) * 1995-06-14 1999-11-29 Schering Ag Novel vitamin d derivatives with c-25 substituents, process for their preparation, intermediate products and their use in preparing medicaments

Also Published As

Publication number Publication date
CN100345547C (zh) 2007-10-31
BR9715022A (pt) 2001-09-18
AU724153B2 (en) 2000-09-14
WO1998029105A3 (en) 1998-10-15
HUP0003526A2 (en) 2001-03-28
NZ336511A (en) 2001-08-31
ATE340581T1 (de) 2006-10-15
EP0951286B1 (en) 2006-09-27
PL334348A1 (en) 2000-02-28
CA2276465A1 (en) 1998-07-09
US5795882A (en) 1998-08-18
KR20000062405A (ko) 2000-10-25
EP0951286A2 (en) 1999-10-27
JP2001512418A (ja) 2001-08-21
WO1998029105A2 (en) 1998-07-09
CN1251527A (zh) 2000-04-26
AU7888398A (en) 1998-07-31
MXPA99006988A (es) 2002-07-02

Similar Documents

Publication Publication Date Title
ATE340581T1 (de) Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
DE69613840D1 (de) Orale dosierungsform und verfahren zur behandlung von schmerzzuständen in dermundhöhle
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
ATE319447T1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
DE69309701D1 (de) Zusammensetzungen mit verzögerter wirkstoffabgabe zur behandlung periodontaler erkrankungen
BR0008397A (pt) Processos para acentuar a absorção celular de uma substância suprida para dentro de uma região alvo do corpo de um paciente, para acentuar a transfecção de dna suprido para dentro de uma região alvo do corpo de um paciente, e para inibir hiperplasia ìntima vascular, sistema de suprimento de energia de ultra-som de campo uniforme e feixe largo, conjuntos para acentuar a absorção celular de uma substância suprida para dentro de uma região alvo do corpo de um paciente, para acentuar a transfecção de dna suprido para dentro de uma região alvo do corpo de um paciente, e para inibir hiperplasia ìntima vascular, e, sistema de suprimento de energia de ultra-som de campo uniforme e feixe largo
ATE296097T1 (de) Verwendung eines r-nsaid als chemoschützendes mittel zur behandlung kolorektales krebs
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
BR0315130A (pt) Composições para terapia celular, terapeuticamente efetivas e de encapsulamento de material biológico, respectivos método e uso
NO20063373L (no) CD40-antistoff-formuleringer og fremgangsmater
DE69737066D1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
ATE300292T1 (de) Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren
ATE222489T1 (de) Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren
PT946151E (pt) Forma de dosagem de dose crescente
ES2171933T3 (es) Derivados de androsteno.
NO305581B1 (no) Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose
DE69914084D1 (de) Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
DE69025271D1 (de) Pharmazeutische Zubereitungen mit verzögerter Freisetzung zur Behandlung periodontaler Erkrankungen
DE59600683D1 (de) Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
US6174541B1 (en) Skin aging and wound treatment using cell migration agents

Legal Events

Date Code Title Description
8332 No legal effect for de